Positive News SentimentPositive NewsNASDAQ:PYPD PolyPid (PYPD) Stock Price, News & Analysis → Get out of dollars—get into America’s new money instead (From Stansberry Research) (Ad) Free PYPD Stock Alerts $4.50 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$4.50▼$4.5050-Day Range$4.25▼$5.0052-Week Range$3.57▼$13.20Volume127 shsAverage Volume1,842 shsMarket Capitalization$21.60 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get PolyPid alerts: Email Address PolyPid MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside211.1% Upside$14.00 Price TargetShort InterestHealthy0.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.59Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.72) to ($2.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.09 out of 5 starsMedical Sector375th out of 929 stocksSurgical & Medical Instruments Industry46th out of 101 stocks 3.5 Analyst's Opinion Consensus RatingPolyPid has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePolyPid has only been the subject of 1 research reports in the past 90 days.Read more about PolyPid's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.53% of the float of PolyPid has been sold short.Short Interest Ratio / Days to CoverPolyPid has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PolyPid has recently decreased by 29.85%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPolyPid does not currently pay a dividend.Dividend GrowthPolyPid does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PYPD. Previous Next 3.1 News and Social Media Coverage News SentimentPolyPid has a news sentiment score of 1.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for PolyPid this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PolyPid insiders have not sold or bought any company stock.Percentage Held by Insiders24.70% of the stock of PolyPid is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 26.47% of the stock of PolyPid is held by institutions.Read more about PolyPid's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PolyPid are expected to grow in the coming year, from ($3.72) to ($2.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PolyPid is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PolyPid is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPolyPid has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about PolyPid's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGet out of dollars—get into America’s new money insteadIs America's New Money right for you? I can't say... but I do know it's 100% legal and available to everyone... although precious few know much about it.Everything you need to know is posted on our website here. About PolyPid Stock (NASDAQ:PYPD)PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.Read More PYPD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PYPD Stock News HeadlinesMay 12, 2024 | investing.comEarnings call: PolyPid reports progress in D-PLEX100 trial, eyes expansionMay 10, 2024 | finance.yahoo.comPolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call TranscriptMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for PolyPid on D-PLEX Progress and Solid Financial FootingMay 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Cartesian Therapeutics (RNAC)May 8, 2024 | investorplace.comPYPD Stock Earnings: PolyPid Beats EPS for Q1 2024May 8, 2024 | globenewswire.comPolyPid Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 1, 2024 | globenewswire.comPolyPid to Participate in Citizens JMP Life Sciences ConferenceApril 30, 2024 | markets.businessinsider.comBuy Rating Affirmed for PolyPid on Strong Trial Progress and Expanding Pipeline PotentialApril 30, 2024 | globenewswire.comPolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site InfectionsApril 24, 2024 | msn.comPYPD: Polypid is Enhancing Surgical OutcomesApril 24, 2024 | globenewswire.comPolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024April 18, 2024 | finance.yahoo.comPolyPid Ltd. (PYPD) Stock Historical Prices & Data - Yahoo FinanceFebruary 28, 2024 | globenewswire.comPolyPid to Participate in Barclays 26th Annual Global Healthcare ConferenceFebruary 19, 2024 | finance.yahoo.comPolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?February 15, 2024 | finance.yahoo.comPolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call TranscriptFebruary 14, 2024 | markets.businessinsider.comBuy Rating for PolyPid Amid Positive D-PLEX100 Trial Prospects and Strategic Market PositioningFebruary 14, 2024 | finanznachrichten.dePolyPid Ltd.: PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 14, 2024 | finance.yahoo.comPolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 14, 2024 | globenewswire.comPolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 12, 2024 | finanznachrichten.dePolyPid Ltd.: PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 TrialFebruary 12, 2024 | finance.yahoo.comPolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 TrialJanuary 31, 2024 | finance.yahoo.comPolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024January 5, 2024 | msn.comWhy Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day SessionJanuary 5, 2024 | msn.comCyclacel Pharmaceuticals, Angiodynamic among healthcare moversJanuary 4, 2024 | uk.finance.yahoo.comPolyPid Ltd. (PYPD)See More Headlines Receive PYPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/31/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PYPD CUSIPN/A CIK1611842 Webwww.polypid.com Phone972-74-719-5700FaxN/AEmployees59Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$14.00 Low Stock Price Target$14.00 Potential Upside/Downside+211.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($12.6439) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-572.69% Return on Assets-110.25% Debt Debt-to-Equity Ratio0.60 Current Ratio1.64 Quick Ratio1.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.49 per share Price / Book3.02Miscellaneous Outstanding Shares4,800,000Free Float3,612,000Market Cap$21.60 million OptionableNo Data Beta1.32 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMs. Dikla Czaczkes Akselbrad (Age 51)CEO & Director Comp: $347.88kMr. Jonny Missulawin (Age 37)Chief Financial Officer Comp: $186.96kMs. Dalit Hazan (Age 53)Executive Vice President of R&D and Clinical & Regulatory Affairs Comp: $272.38kMr. Ori Warshavsky (Age 46)Chief Operating Officer - US Comp: $340.89kMs. Maria RubinVice President of OperationsMr. Tal VilnaiGeneral Counsel & Corporate SecretaryMs. Rivi Lev-ariVice President of Human ResourceDr. Jean-Marc Hagai Pharm.D.Chief Commercial OfficerMore ExecutivesKey CompetitorsLyra TherapeuticsNASDAQ:LYRAT2 BiosystemsNASDAQ:TTOOiCADNASDAQ:ICADApyx MedicalNASDAQ:APYXMural OncologyNASDAQ:MURAView All CompetitorsInstitutional OwnershipRosalind Advisors Inc.Bought 415,800 shares on 4/25/2024Ownership: 8.668%View All Institutional Transactions PYPD Stock Analysis - Frequently Asked Questions Should I buy or sell PolyPid stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PolyPid in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PYPD shares. View PYPD analyst ratings or view top-rated stocks. What is PolyPid's stock price target for 2024? 1 analysts have issued 1-year target prices for PolyPid's stock. Their PYPD share price targets range from $14.00 to $14.00. On average, they predict the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 211.1% from the stock's current price. View analysts price targets for PYPD or view top-rated stocks among Wall Street analysts. How have PYPD shares performed in 2024? PolyPid's stock was trading at $3.80 on January 1st, 2024. Since then, PYPD stock has increased by 18.4% and is now trading at $4.50. View the best growth stocks for 2024 here. Are investors shorting PolyPid? PolyPid saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 4,700 shares, a decrease of 29.9% from the April 30th total of 6,700 shares. Based on an average trading volume of 2,500 shares, the days-to-cover ratio is currently 1.9 days. Currently, 0.5% of the company's stock are sold short. View PolyPid's Short Interest. When is PolyPid's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our PYPD earnings forecast. How were PolyPid's earnings last quarter? PolyPid Ltd. (NASDAQ:PYPD) posted its quarterly earnings data on Wednesday, May, 8th. The company reported ($1.37) earnings per share for the quarter, topping analysts' consensus estimates of ($1.96) by $0.59. When did PolyPid's stock split? PolyPid shares reverse split before market open on Thursday, September 21st 2023. The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of PolyPid own? Based on aggregate information from My MarketBeat watchlists, some companies that other PolyPid investors own include Advanced Micro Devices (AMD), Moderna (MRNA), Sorrento Therapeutics (SRNE), Trevena (TRVN), Cardinal Health (CAH), Genocea Biosciences (GNCA), LightPath Technologies (LPTH), Stride (LRN) and Livongo Health (LVGO). When did PolyPid IPO? PolyPid (PYPD) raised $50 million in an initial public offering on Friday, June 26th 2020. The company issued 3,100,000 shares at $15.00-$17.00 per share. Barclays and BMO Capital Markets served as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers. Who are PolyPid's major shareholders? PolyPid's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Rosalind Advisors Inc. (8.67%). How do I buy shares of PolyPid? Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PYPD) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaGet out of dollars—get into America’s new money insteadStansberry ResearchThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWrite this ticker symbol down…StocksToTradeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks MediaElon Musk’s Final Masterpiece: “X-9840”Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
